Participants with a loop ileostomy following anterior resection for colorectal cancer. Cancer
Conditions
Interventions
All participants take two O3FA containing soft gel capsules twice daily with meals (total 1000 mg EPA and 1000 mg DHA daily) for 4 weeks. They are asked to provide a stoma fluid sample at 3 separate
Sponsors
University of Leeds (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Aged 50 years or over 2. Either gender 3. Temporary ileostomy fashioned at least 2 months prior to commencing study 4. Able to self medicate 5. A minimum period of 2 months availability for the study prior to planned ileostomy reversal
Exclusion criteria
Exclusion criteria: 1. Seafood allergy 2. Ongoing and/or previous use (within 4 weeks of commencing the study) of other O3FA or cod-liver oil supplements 3. Previous small bowel resection 4. Metastatic colorectal cancer 5. Less than 4 weeks since any chemotherapy or radiotherapy 6. Inflammatory bowel disease or other intestinal disease (e.g. coeliac disease)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in terminal ileal fluid EPA and DHA concentration at four weeks compared with baseline. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Change in percentage erythrocyte membrane content of EPA and DHA at four weeks compared with baseline. 2. Change in terminal ileal fluid EPA and DHA concentration within 24 hours of taking the first O3FA dose. 3. Tolerability and adverse events related to O3FA supplementation. | — |
Countries
England, United Kingdom
Outcome results
None listed